Septerna (SEPN) Cash from Investing Activities (2023 - 2026)
Septerna (SEPN) recorded quarterly Cash from Investing Activities of -$23.8 million in Q1 2026, up 87.15% quarter-over-quarter from -$185.3 million in Q4 2025, and down 388.65% on a YoY basis from $8.3 million in Q1 2025.
Septerna (SEPN) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Septerna's Cash from Investing Activities history runs 4 years deep, the most recent figure standing at -$23.8 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 388.65% year-over-year to -$23.8 million; the TTM figure through Mar 2026 stood at -$248.3 million (down 41.85% YoY), while the FY2025 annual figure was -$229.4 million, down 42.81% from the prior year.
- Cash from Investing Activities was -$23.8 million for Q1 2026 at Septerna, up from -$185.3 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $9.6 million in Q1 2024 to a low of -$185.3 million in Q4 2025.
- Historically, Cash from Investing Activities has averaged -$41.5 million across 4 years, with a median of -$18.0 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities sank 10653.75% in 2024, then jumped 93.52% in 2025.
- A 4-year view of Cash from Investing Activities shows it stood at -$1.2 million in 2023, then tumbled by 10653.75% to -$133.2 million in 2024, then sank by 39.07% to -$185.3 million in 2025, then surged by 87.15% to -$23.8 million in 2026.
- The last three Cash from Investing Activities figures came in at -$23.8 million (Q1 2026), -$185.3 million (Q4 2025), and -$38.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Septerna | 1.62 Bn | 1.62 Bn | - | -23.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.82 Mn |
| Mar 31, 2026 | -23.82 Mn |
| Dec 31, 2025 | -185.30 Mn |
| Dec 31, 2025 | -185.30 Mn |
| Sep 30, 2025 | -38.39 Mn |
| Sep 30, 2025 | -38.39 Mn |
| Jun 30, 2025 | -786,000.00 |
| Jun 30, 2025 | -786,000.00 |
| Mar 31, 2025 | -4.87 Mn |
| Mar 31, 2025 | -4.87 Mn |
| Dec 31, 2024 | -133.24 Mn |
| Dec 31, 2024 | -133.24 Mn |
| Sep 30, 2024 | -24.79 Mn |
| Sep 30, 2024 | -24.79 Mn |
| Jun 30, 2024 | -12.13 Mn |
| Jun 30, 2024 | -12.13 Mn |
| Mar 31, 2024 | 9.57 Mn |
| Mar 31, 2024 | 9.57 Mn |
| Dec 31, 2023 | -1.24 Mn |
| Dec 31, 2023 | -1.24 Mn |